Background Glucose deprivation inhibits T-cell metabolism and function. Glucose levels are low in the tumor microenvironment of solid tumors and insufficient glucose uptake limits the antitumor response of T cells. Furthermore, glucose restriction can contribute to the failure of chimeric antigen receptor T (CAR-T) cell therapy for solid tumors. However, the impact of glucose restriction… Continue reading Glut3 overexpression improves environmental glucose uptake and antitumor efficacy of CAR-T cells in solid tumors
Tag: Biochemical Pharmacology
Differential roles of human CD4+ and CD8+ regulatory T cells in controlling self-reactive immune responses
Abstract Here we analyzed the relative contributions of CD4+ regulatory T cells expressing Forkhead box protein P3 (FOXP3) and CD8+ regulatory T cells expressing killer cell immunoglobulin-like receptors to the control of autoreactive T and B lymphocytes in human tonsil-derived immune organoids. FOXP3 and GZMB respectively encode proteins FOXP3 and granzyme B, which are critical… Continue reading Differential roles of human CD4+ and CD8+ regulatory T cells in controlling self-reactive immune responses
Biophysical mapping of TREM2-ligand interactions reveals shared surfaces for engagement of multiple Alzheimer’s disease ligands
TREM2 is a signaling receptor expressed on microglia that has emerged as an important drug target for Alzheimer’s disease and other neurodegenerative diseases. While a number of TREM2 ligands have been identif…
[ASAP] Phenotype-Led Identification of IL-10 Upregulators in Human CD4+ T-cells and Elucidation of Their Pharmacology as Highly Selective CDK8/CDK19 Inhibitors
Breaking the energy chain: importance of ATP synthase in Mycobacterium tuberculosis and its potential as a drug target
Unveiling novel pathways for drug discovery forms the foundation of a new era in the combat against tuberculosis. The discovery of a novel drug, bedaquiline, targeting mycobacterial ATP synthase highlighted the targetability of the energy metabolism pathway. The significant potency of bedaquiline against heterogeneous population of Mycobacterium tuberculosis marks ATP synthase as an important complex… Continue reading Breaking the energy chain: importance of ATP synthase in Mycobacterium tuberculosis and its potential as a drug target
Novel and potent MICA/B antibody is therapeutically effective in KRAS LKB1 mutant lung cancer models
Background Concurrent KRAS LKB1 (STK11, KL) mutant non-small cell lung cancers (NSCLC) do not respond well to current immune checkpoint blockade therapies, however targeting major histocompatibility complex class I-related chain A or B (MICA/B), could pose an alternative therapeutic strategy through activation of natural killer (NK) cells. Methods Expression of NK cell activating ligands in… Continue reading Novel and potent MICA/B antibody is therapeutically effective in KRAS LKB1 mutant lung cancer models
MIT affiliates awarded 2024 National Medals of Science, Technology
Four MIT faculty members are among 23 world-class researchers who have been awarded the nation’s highest honors for scientists and innovators, the White House announced today. Angela Belcher and Emery Brown were each presented with the National Medal of Science at a White House ceremony this afternoon, and Paula Hammond ’84, PhD ’93, and Feng… Continue reading MIT affiliates awarded 2024 National Medals of Science, Technology
Feng Zhang awarded 2024 National Medal of Technology
This post is adapted from an MIT News story. *** Four MIT faculty members are among 23 world-class researchers who have been awarded the nation’s highest honors for scientists and innovators, the White House announced today. Angela Belcher and Emery Brown were each presented with the National Medal of Science at a White House ceremony… Continue reading Feng Zhang awarded 2024 National Medal of Technology
FDA Approvals in Oncology: October-December 2024
To help our readers keep track of the cancer therapies approved by the U.S. Food and Drug Administration (FDA), understand their impact for patients, and put them in context of the current therapeutic landscape, Cancer Research Catalyst provides a quarterly review of the latest approvals in oncology from the FDA. The FDA had a busy 2024, issuing… Continue reading FDA Approvals in Oncology: October-December 2024
Editors’ Picks, December 2024: Immunosuppression in the Lung, New Mathematical Models, and More
As we ring in 2025, Cancer Research Catalyst wishes you a very Happy New Year! May your 2025 be full of love, connection, and inspiration. As always, we love to keep you connected with inspiring cancer research by sharing this month’s editors’ picks from the 10 American Association for Cancer Research (AACR) journals. December’s holiday… Continue reading Editors’ Picks, December 2024: Immunosuppression in the Lung, New Mathematical Models, and More